Lack of a primary physicochemical determinant in the direct transport of drugs to the brain after nasal administration in rats: Potential involvement of transporters in the pathway

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 5, 2010, Pages 430-441

  Lee, Kyeong Ryoon ^a   Maeng, Han Joo ^a   Chae, Jung Byung ^a   Chong, Saeho ^a   Kim, Dae Duk ^a   Shim, Chang Koo ^a   Chung, Suk Jae ^a  

^a Seoul National University   (South Korea)

Author keywords

Blood brain barrier; Brain; Central nervous system; Nasal administration; Olfactory pathway; Pharmacokinetics

Indexed keywords

ATENOLOL; CAFFEINE; CHLOROTHIAZIDE; DONEPEZIL; FEXOFENADINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METFORMIN; METOPROLOL; NAPROXEN; OFLOXACIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PIROXICAM; QUINIDINE; QUININE; RANITIDINE; TETRACYCLINE; THEOPHYLLINE;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TRANSPORT; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KINETICS; MALE; MEMBRANE PERMEABILITY; NONHUMAN; OLFACTORY EPITHELIUM; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLUBILITY;

EID: 78449263625     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-049     Document Type: Article

References (62)

1. Vyas, T. K., Shahiwala, A., Marathe, S. and Misra, A.: Intranasal drug delivery for brain targeting. Curr. Drug Del., 2: 165-175 (2005).
2. Pardridge, W. M.: The blood-brain barrier: bottleneck in brain drug development. NeuroRx, 2: 3-14 (2005).
3. Lockman, P. R., Mumper, R. J., Khan, M. A. and Allen, D. D.: Nanoparticle technology for drug delivery across the bloodbrain barrier. Drug Dev. Ind. Pharm., 28: 1-13 (2002).
4. Misra, A., Ganesh, S., Shahiwala, A. and Shah, S. P.: Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci., 6: 252-273 (2003).
5. Tamai, I. and Tsuji, A.: Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci., 89: 1371-1388 (2000).
6. Kusuhara, H. and Sugiyama, Y.: Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discovery Today, 6: 206-212 (2001).
7. Ghersi-Egea, J. F., Minn, A. and Siest, G.: A new aspect of the protective functions of the blood-brain barrier: Activities of four drug-metabolizing enzymes in isolated rat brain microvessels. Life Sci., 42: 2515-2523 (1988).
8. Ghersi-Egea, J. F., Leininger-Muller, B., Cecchelli, R. and Fenstermacher, J. D.: Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol. Lett., 82: 645-653 (1995).
9. Illum, L.: Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci., 11: 1-18 (2000).
10. Shi, Z., Zhang, Q. and Jiang, X.: A novel method to calculate the extent and amount of drug transported into CSF after intranasal administration. Int. J. Pharm., 289: 159-166 (2005).
11. Tü rker, S., Onur, E. and OÁzer, Y.: Nasal route and drug delivery systems. Pharm. World Sci., 26: 137-142 (2004).
12. Marttin, E., Verhoef, J. C., Spies, F., Van der Meulen, J., Nagelkerke, J. F., Koerten, H. K. and Merkus, F.: The effect of methylated [beta]-cyclodextrins on the tight junctions of the rat nasal respiratory epithelium: Electron microscopic and confocal laser scanning microscopic visualization studies. J. Controlled Release, 57: 205-213 (1999).
13. Talegaonkar, S. and Mishra, P. R.: Intranasal delivery: An approach to bypass the blood brain barrier. Ind. J. Pharmcol., 36: 140 (2004).
14. Barakat, N. S., Omar, S. A. and Ahmed, A. A. E.: Carbamazepine uptake into rat brain following intra-olfactory transport. J. Pharm. Pharmacol., 58: 63-72 (2006).
15. Thorne, R. G., Pronk, G. J., Padmanabhan, V. and Frey, W. H.: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 127: 481-496 (2004).
16. Thorne, R. G., Hanson, L. R., Ross, T. M., Tung, D. and Frey, W. H. II: Delivery of interferon-[beta] to the monkey nervous system following intranasal administration. Neuroscience, 152: 785-797 (2008).
17. Thorne, R. G., Emory, C. R., Ala, T. A. and Frey, W.H. II: Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res., 692: 278-282 (1995).
18. Dahlin, M., Bergman, U., Jansson, B., Bjoärk, E. and Brittebo, E.: Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm. Res., 17: 737-742 (2000).
19. Gao, X., Tao, W., Lu, W., Zhang, Q., Zhang, Y., Jiang, X. and Fu, S.: Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials, 27: 3482-3490 (2006).
20. Sigurdsson, P. Á. L., Thorvaldsson, T., Gizurarson, S. Ö. R. and Gunnarsson, E.: Olfactory absorption of insulin to the brain. Drug Deliv., 4: 195-200 (1997).
21. Vyas, T. K., Babbar, A. K., Sharma, R. K., Singh, S. andMisra, A.: Intranasal mucoadhesive microemulsions of clonazepam: Preliminary studies on brain targeting. J. Pharm. Sci., 95: 570 (2006).
22. Kim, K. P., Ahn, S. H., Sung, J. H., Koo, T. S., Byun, M. J., Kim, D. D., Shim, C. K. and Chung, S. J.: Application of a sample pooling method for the accelerated assessment of the rate of uptake of drugs by the brain in rats. J. Pharm. Pharmacol., 58: 837-846 (2006).
23. Van Den Berg, M. P., Romeijn, S. G., Verhoef, J. and Merkus, F. W. H. M.: Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J. Neurosci. Methods, 116: 99-107 (2002).
24. Bagger, M. A. and Bechgaard, E.: The potential of nasal application for delivery to the central brain-a microdialysis study of fluorescein in rats. Eur. J. Pharm. Sci., 21: 235-242 (2004).
25. Gao, X., Chen, J., Tao, W., Zhu, J., Zhang, Q., Chen, H. and Jiang, X.: UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int. J. Pharm., 340: 207-215 (2007).
26. FDA: Guidance for industry: bioanalytical method validation. 2001, Rockville, MD: CDER.
27. Xie, Z., Liao, Q., Xu, X., Yao, M., Wan, J. and Liu, D.: Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun. Mass Spectrom., 20: 3193-3198 (2006).
28. Kim, M.H., Maeng, H. J., Yu, K. H., Lee, K. R., Tsuruo, T., Kim, D. D., Shim, C. K. and Chung, S. J.: Evidence of carrier-mediated transport in the penetration of donepezil into the rat brain. J. Pharm. Sci., 99: 1548-1566 (2009).
29. Wolburg, H., Wolburg-Buchholz, K., Sam, H., Horvat, S., Deli, M. A. and Mack, A. F.: Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat. Histochem. Cell Biol., 130: 127-140 (2008).
30. Graff, C. L. and Pollack, G. M.: Functional evidence for Pglycoprotein at the nose-brain barrier. Pharm. Res., 22: 86-93 (2005).
31. Ahn, S. H., Jeon, S. H., Tsuruo, T., Shim, C. K. and Chung, S. J.: Pharmacokinetic characterization of dehydroevodiamine in the rat brain. J. Pharm. Sci., 93: 283-292 (2003).
32. Chou, K. J. and Donovan, M. D.: The distribution of local anesthetics into the CSF following intranasal administration. Int. J. Pharm., 168: 137-145 (1998).
33. Koepsell, H.: Organic cation transporters in intestine, kidney, liver, and brain. Annu. Rev. Physiol., 60: 243-266 (1998).
34. Tsuji, A. and Tamai, I.: Carrier-mediated intestinal transport of drugs. Pharm. Res., 13: 963-977 (1996).
35. Tahara, H., Kusuhara, H., Chida, M., Fuse, E. and Sugiyama, Y.: Is the monkey an appropriate animal model to examine drugdrug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J. Pharmacol. Exp. Ther., 316: 1187 (2006).
36. Rizwan, A. N. and Burckhardt, G.: Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res., 24: 450-470 (2007).
37. Bachmakov, I., Glaeser, H., Endress, B., Mäorl, F., König, J. and Fromm, M. F.: Interaction of beta-blockers with the renal uptake transporter OCT2. Diabetes Obes. Metab., 11: 1080-1083 (2009).
38. zu Schwabedissen, M., Henriette, E., Verstuyft, C., Kroemer, H. K., Becquemont, L. and Kim, R. B.: Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: Functional characterization, interaction with OCT2, and single nucleotide polymorphisms. Am. J. Physiol. Renal. Physiol., 298: F997-F1005 (2010).
39. Koepsell, H. and Endou, H.: The SLC22 drug transporter family. Pflü gers Arch., 447: 666-676 (2004).
40. Hosoya, K., Hori, S., Ohtsuki, S. and Terasaki, T.: A new in vitro model for blood-cerebrospinal fluid barrier transport studies: an immortalized choroid plexus epithelial cell line derived from the tsA58 SV40 large T-antigen gene transgenic rat. Adv. Drug Del. Rev., 56: 1875-1885 (2004).
41. Illum, L.: Nasal delivery. The use of animal models to predict performance in man. J. Drug Targeting, 3: 427-442 (1996).
42. Illum, L.: Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol., 56: 3-17 (2004).
43. Forbes, B., Shah, A., Martin, G. P. and Lansley, A. B.: The human bronchial epithelial cell line 16HBE14o- as a model system of the airways for studying drug transport. Int. J. Pharm., 257: 161-167 (2003).
44. Dias, M., Hadgraft, J. and Lane, M. E.: Influence of membranesolvent- solute interactions on solute permeation in skin. Int. J. Pharm., 340: 65-70 (2007).
45. Kontoyannis, C. G. and Antimisiaris, G.: Simultaneous quantitative determination of diazepam and liposomes using differential pulse polarography. Anal. Chim. Acta, 391: 83-88 (1999).
46. Ibrahim, F., André, C., Thomassin, M. and Guillaume, Y. C.: Association mechanism of four acetylcholinesterase inhibitors (AChEIs) with human serum albumin: A biochromatographic approach. J. Pharm. Biomed. Anal., 48: 1345-1350 (2008).
47. Zhao, R., Kalvass, J. C. and Pollack, G. M.: Assessment of bloodbrain barrier permeability using the in situ mouse brain perfusion technique. Pharm. Res., 26: 1657-1664 (2009).
48. Faller, B. and Wohnsland, F.: Physicochemical parameters as tools in drug discovery and lead optimization. Weinheim, Germany, VHCA & WILEY-VCH, 2001.
49. Giddings, J. C. and Keller, R. A.: Advances in chromatography. CRC, 1989.
50. Obata, K., Sugano, K., Machida, M. and Aso, Y.: Biopharmaceutics classification by high throughput solubility assay and PAMPA. Drug Dev. Ind. Pharm., 30: 181-185 (2004).
51. Chiang, P. C. and Hu, Y.: Simultaneous determination of LogD, LogP, and pKa of drugs by using a reverse phase HPLC coupled with a 96-well plate auto injector. Combinatorial Chem. High Throughput Screening, 12: 250-257 (2009).
52. Austin, R. P., Barton, P., Cockroft, S. L., Wenlock, M. C. and Riley, R. J.: The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Disposition, 30: 1497 (2002).
53. Hou, T. J., Zhang, W., Xia, K., Qiao, X. B. and Xu, X. J.: ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. J. Chem. Inf. Comput. Sci., 44: 1585-1600 (2004).
54. Van De Waterbeemd, H., Lennernäs, H. and Artursson, P.: Drug bioavailability: estimation of solubility, permeability, absorption and bioavailability. Weinheim, Germany: WILEY-VCH, 2003.
55. Nicklin, P., Keates, A. C., Page, T. and Bailey, C. J.: Transfer of metformin across monolayers of human intestinal Caco-2 cells and across rat intestine. Int. J. Pharm., 128: 155-162 (1996).
56. Sugano, K., Hamada, H., Machida, M., Ushio, H., Saitoh, K. and Terada, K.: Optimized conditions of bio-mimetic artificial membrane permeation assay. Int. J. Pharm., 228: 181-188 (2001).
57. Arce, M. P., Rodriguez-Franco, M. I., Gonzalez-Munoz, G. C., Perez, C., Lopez, B., Villarroya, M., Lopez, M. G., Garcia, A. G. and Conde, S.: Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. J. Med. Chem., 52: 7249-7257 (2009).
58. Poirier, A., Funk, C., Scherrmann, J. M. and Lave, T.: Mechanistic modeling of hepatic transport from cells to whole body: Application to napsagatran and fexofenadine. Mol. Pharm., 6: 1716-1733 (2009).
59. Kovo, M., Kogman, N., Ovadia, O., Nakash, I., Golan, A. and Hoffman, A.: Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat. Diagn., 28: 544-548 (2008).
60. Liu, H., Sabus, C., Carter, G. T., Du, C., Avdeef, A. and Tischler, M.: In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection. Pharm. Res., 20: 1820-1826 (2003).
61. Avdeef, A., Nielsen, P. E. and Tsinman, O.: PAMPA-a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. Eur. J. Pharm. Sci., 22: 365-374 (2004).
62. Teksin, Z. S., Seo, P. R. and Polli, J. E.: Comparison of drug permeabilities and BCS classification: Three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J., 12: 238-241 (2010).